1.51
1.51 (0%)
As of Apr 28, 2025
Biodexa Pharmaceuticals Plc [BDRX]
Source:
Company Overview
Biodexa Pharmaceuticals Plc is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medicalneeds, including familial adenomatous polyposis, or FAP, non-muscle invasive bladder cancer, or NMIBC, type 1 diabetes, or T1D, and rare/orphancancers of the brain.
| Country | United Kingdom |
| Headquarters | cardiff |
| Phone Number | 44 (0)1235 888300 |
| Industry | manufacturing |
| CEO | Stephen Stamp |
| Website | biodexapharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-9.2 |
| Net Income | $-5.7 |
| Net Cash | $-4.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -45.3% |
| Profit as % of Stockholder Equity | -68.8% |
Management Effectiveness
| Return on Equity | -68.8% |
| Return on Assets | -38.8% |
| Turnover Ratio | |
| EBITA | $-9.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $14.8 |
| Total Liabilities | $6.5 |
| Operating Cash Flow | $-12.3 |
| Investing Cash Flow | $-0.6 |
| Financing Cash Flow | $8.6 |
